TRIMETHOPRIM (trimethoprim) by Dr. Reddy's Laboratories is dihydrofolate reductase inhibitors [moa]. First approved in 1982.
Drug data last refreshed 19h ago · AI intelligence enriched 3d ago
Trimethoprim is a small-molecule oral dihydrofolate reductase inhibitor approved in 1982 for bacterial infections. It works by inhibiting bacterial folate synthesis, preventing nucleotide production essential for bacterial growth. This antibiotic is primarily used for urinary tract infections and other bacterial infections.
Minimal commercial activity with very low Part D spending and claims volume suggests a mature, niche product with limited team expansion.
Dihydrofolate Reductase Inhibitors
Dihydrofolate Reductase Inhibitor Antibacterial
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP
Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment
PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children
Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers
Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi
Worked on TRIMETHOPRIM at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moTrimethoprim offers minimal career advancement given its mature, post-LOE status and negligible commercial activity. Roles available are primarily in generic optimization, compliance, and supply chain rather than innovation or growth.